Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alloy Inks Cell Therapy Deal with Takeda, Japan Outpost to Launch by Month-End
US biotech Alloy Therapeutics said on November 20 that it has struck a license and collaboration pact with Takeda Pharmaceutical to develop the Japanese giant’s cell therapy platforms. Subject to the deal are Takeda’s proprietary iPSC-derived CAR-T cell platform (iCAR-T)…
To read the full story
Related Article
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
- Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
- Alloy Japan Teams with KSAC to Back University Startups’ Global Push
July 23, 2025
- Alloy Japan Now Up and Running to Deliver iCAR-T for Cancer Therapy Development
May 22, 2025
BUSINESS
- Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry
February 4, 2026
- Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope
February 4, 2026
- Takeda, Kyoto University to End T-CiRA iPS Cell Program after 10 Years
February 4, 2026
- Fuji, Richter Expand Gynecology Partnership to Accelerate R&D
February 4, 2026
- Senju, Novartis Ink Promotion Tie-Up for Eye Drug Beovu in Japan
February 4, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…